表柔比星联合紫杉醇在三阴性乳腺癌新辅助化疗中的临床效果分析

Clinical Analysis of Epirubicin Combined with Paclitaxel in Neoadjuvant Chemotherapy for Triple Negative Breast Cancer

目的分析三阴性乳腺癌采用表柔比星和紫杉醇联合治疗的效果。方法纳入该院2017年1月—2019年1月期间接诊的88例三阴性乳腺癌(初治Ⅲ期)患者,使用随机数字表法将患者平均分为对照组和观察组,44例/组,对照组接受紫杉醇联合卡铂治疗,观察组接受表柔比星和紫杉醇联合治疗,将两组三阴性乳腺癌患者治疗效果比较。结果观察组治疗后肿瘤直径缩小大于对照组,差异有统计学意义(t=5.688,P=0.000)。(观察组CR 25.00%,PR 68.18%,SD 4.55%,PD2.27%,总有效率93.18%;对照组CR36.36%,PR 36.36%,SD 15.91%,PD11.36%,总有效率72.73%)。观察组有效率高于对照组,差异有统计学意义(χ^2=6.510,P=0.011)。两组三阴性乳腺癌患者不良反应两组相似(χ^2=0.039,P=0.534)。结论三阴性乳腺癌采用表柔比星和紫杉醇联合治疗效果显著,两组不良反应无明显差别,耐受性好,无化疗相关死亡,值得予以使用推广。

Objective To analyze the effect of combination therapy with epirubicin and paclitaxel in triple-negative breast cancer.Methods Eighty-eight patients with triple-negative breast cancer(initial phase III)who were admitted to the hospital from January 2017 to January 2019 were randomly divided into control group and observation group,44 cases/group,the control group received paclitaxel combined with carboplatin,the observation group received combination of epirubicin and paclitaxel,the treatment effect of the two groups of triple-negative breast cancer patients.Results The diameter of the tumor in the observation group was larger than that in the control group after treatment,and the difference was statistically significant(t=5.688,P=0.000).(View group CR 25.00%,PR 68.18%,SD 4.55%,PD 2.27%,total effective rate 93.18%;control group CR36.36%,PR 36.36%,SD 15.91%,PD 11.36%,total effective rate 72.73%).The observation group was more effective than the control group,and the difference was statistically significant(χ^2=6.510,P=0.011).The adverse reactions of the three groups of triple-negative breast cancer patients were similar(χ^2=0.039,P=0.534).Conclusion The combination of epirubicin and paclitaxel in triple-negative breast cancer is effective.There is no significant difference in adverse reactions between the two groups.It is well tolerated and has no chemotherapy-related death.It is worthy of being used.